Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma

Omalizumab is recommended as an add-on therapy in patients aged ≥6 years with inadequately controlled, moderate-to-severe persistent allergic asthma. The efficacy and safety of omalizumab treatment in allergic asthma clinical trials and its effectiveness in the real world have been reported in numer...

Descripción completa

Detalles Bibliográficos

Autores principales:	Nicola A. Hanania, MD, Robert Niven, MD, Pascal Chanez, MD, PhD, Deschildre Antoine, MD, PhD, Pascal Pfister, MD, Lorena Garcia Conde, MD, Xavier Jaumont, MD
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2022-10-01
Colección:	World Allergy Organization Journal
Materias:	Allergic asthma Efficacy Long-term Omalizumab Safety Pediatric
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S1939455122000710
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!